CU-906

CU-906 is a **preclinical small molecule drug candidate** developed by Curis that acts as a dual inhibitor of **histone deacetylase (HDAC)** and the **PI3K/mTOR pathway**. It was designed to achieve simultaneous inhibition of these targets in cancer therapy, with the aim of improving antitumor activity by addressing both epigenetic regulation (HDAC) and key oncogenic signaling (PI3K/mTOR). Preclinical data demonstrated the compound’s antitumor activity and rationale for single-agent multi-target inhibition in cancer. CU-906 served as an early research compound that informed the development of clinically advanced molecules like CUDC-907, but CU-906 itself does not appear to have entered clinical trials[1][4][7][18].